Work

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies

Year: 2026

Type: article

Abstract: We read with great interest the article by Okemoto et al. investigating the association between claudin 18.2 (CLDN18.2) expression and clinical outcomes of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction cancer.1 While the study addresses a clinically significant question, we would like to highlight several methodological concerns that may affect the interpretation of the findings.

Source: ESMO Gastrointestinal Oncology

DOI: 10.1016/j.esmogo.2026.100316

Author: Kenichi Yoshimura

Institution: Nagoya City University

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170